Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo

KRISTOPHER R. GRIMES¹, GRAHAM W. WARREN², FANG FANG³, YONG XU³ and WILLIAM H. ST. CLAIR¹,²

¹Graduate Center for Nutritional Sciences, ²Radiation Medicine, ³Graduate Center of Toxicology, University of Kentucky, Lexington, KY, USA

Received February 13, 2006; Accepted April 17, 2006

Abstract. Lung cancer is the leading cause of cancer-related deaths in the United States. Despite improvements in radiation, surgery and chemotherapy the 5 year survival statistics of non-small cell lung cancer (NSCLC) have improved little over the past two decades. It has been proposed that NF-κB is a participant in the cytoprotection against several redox-mediated therapeutic agents including ionizing radiation. Cyclooxygenase-2 (COX-2) inhibition has become an attractive target for enhancing the efficacy of radiation and chemotherapy. Numerous mechanistic pathways have been proposed as the means through which COX-2 inhibition enhances the efficacy of radiation. We hypothesize that the COX-2 inhibitor, nimesulide, will improve the efficacy of radiation therapy (RT), at least in part, via the suppression of NF-κB mediated cytoprotective pathways. In this study we used the COX-2 inhibitor nimesulide to improve the efficacy of RT when measured by tumor regrowth assays in vivo and clonogenic survival in vitro. For the in vitro assay, A549 tumor cells representing NSCLC were subcutaneously injected into the right flanks of female athymic nude mice (n=10/group). Mice were given nimesulide via drinking water at a concentration of 5 μg/g body weight (b.w.) and the water was replenished daily. Tumors were treated with 30 Gy fractionated radiation and measured bi-weekly. For our in vitro study, clonogenic survival assays were evaluated to determine the effect of nimesulide, radiation, and the combination. The NF-κB mediated mechanism of nimesulide was measured by Western blot analysis of NF-κB target genes, MnSOD and survivin. In vivo, mice that received combined treatments of 5 μg/g b.w. nimesulide and 30 Gy radiation (3 Gy/fraction, 10 daily fractions) had significant reduction in tumor size in comparison to the 30 Gy radiation control group (p<0.05). In vitro, nimesulide alone produced a significant decrease in clonogenic survival at doses from 0.300 μM. Nimesulide demonstrated an additive effect in combination with radiation. Nimesulide alone reduced MnSOD and survivin protein levels in a dose-dependent manner. 6 Gy radiation caused an initial elevation of MnSOD protein levels which was inhibited by prior treatment of nimesulide suggesting an inhibition of radiation induced NF-κB target genes. These results support the hypothesis that COX-2 inhibitors such as nimesulide can increase the efficacy of radiation therapy. In vitro, our results suggest that the radiosensitization of A549 tumor cells by nimesulide is mediated by the suppression of NF-κB-mediated, radiation-induced cytoprotective genes.

Introduction

The COX family of enzymes plays a primary role in the conversion of arachidonic acid (AA) into a variety of prostaglandins, prostacyclins and thromboxanes through a diverse set of reactions in response to and mediation of cellular inflammatory signals (1-4). There are two main isoforms within the COX family, COX-1 and COX-2, both acting on the same substrate, arachidonic acid, but with distinct regulational expression. COX-1 is generally referred to as a ‘house-keeping’ protein that is constitutively expressed and is most notably associated with the maintenance of the gastrointestinal mucosa. COX-2 on the other hand is an inducible isoform that is usually expressed at low basal levels until stimulated by many inflammatory mediators such as TNF-α and EGF (5). Recently, COX-2 has become a target for therapeutic intervention in the treatment of cancer, most notably that of colorectal origin (1,5). With mounting evidence that specific inhibitors of COX-2 could prove beneficial in combination with conventional means of cancer treatment, such as radiation, we feel that inhibition of COX-2 may improve the radiosensitization of NSCLC.

Studies, both pre-clinical and clinical, have demonstrated that COX-2 has a critical role in several mechanisms that promote cancer development. Much of the current research is focused on the enzyme’s role in angiogenesis, apoptosis, metastasis, cell cycle control and potential transcriptional regulation of certain tumor promoting events. Hong et al
demonstrated that the selective COX-2 inhibitor nimesulide decreased tumor growth in vivo by overexpression of pro-apoptotic Bax in relation to anti-apoptotic Bcl-2, thus, promoting cell death (6). Hsu et al. showed that celecoxib was able to induce apoptosis by blocking Akt activation in prostate cancer (7). Another strong focus has been placed on NSAID roles in suppression of angiogenesis whereby increasing concentrations of different COX-2 inhibitors have a negative impact on VEGF production while reducing overall tumor growth and proliferation which may have strong implications on metastasis and cell cycle regulation (8-11). It is evident that inhibition of COX-2 could alter many cellular cascades leading eventually to cell death and/or tumor suppression. However, the specific mechanism of how COX-2 inhibition mediates transcriptional regulation is still relatively unclear.

NF-κB has been shown to be an antagonist to chemoradiotherapy due to the regulation of specific cytoprotective genes such as sod 2 (MnSOD), survivin, as well as cox-2. Radiation-induced reactive oxygen species (ROS) production increases redox sensitive NF-κB activity and it has been shown that the NF-κB pathway will result in cytoprotection of targeted tissues (12-14). By suppressing radiation-induced NF-κB we hypothesize that tumors will become more vulnerable to radiation insult. It has previously been shown that NF-κB can be positively regulated by prostaglandin E 2 (PGE2), the major product of COX-2-mediated AA metabolism. This activation occurs through PGE2’s ability to activate the transactivation domain of p65 (15). Interestingly, as previously mentioned, COX-2 is also regulated by NF-κB through two κB sites within the promoter region of the gene (5,15,16). Furthermore, it has also been shown that under stress, like radiation, elevated amounts of AA are released from the inner cellular membrane. This correlates with increased COX-2 expression and PGE2 levels (1,17). This information allows for the potential to combine specific COX-2 inhibitors with conformal ionizing radiation to enhance therapeutic efficacy while avoiding typical systemic toxicities accustomed with standard chemotherapy.

We hypothesize that by administering nimesulide, a selective COX-2 inhibitor, both in vitro and in vivo, radiation-induced NF-κB activity and target cytoprotective proteins will be suppressed. To test this hypothesis, we used an in vitro model to determine the effectiveness of nimesulide in improving the overall efficacy of radiation treatment. In vitro we observed effects of nimesulide and radiation on cell survival and NF-κB target protein induction. We conclude that nimesulide improves radiation therapy against NSCLC in part by suppressing radiation-induced NF-κB-targeted cytoprotection.

Materials and methods

In vivo studies. Six week-old nude mice (NCR nu/nu athymic nude mice), female, weighing 20-24 g (Harlan Labs) were injected with 4x10⁶ A549 cells, suspended in 75 μl of FBS-free RPMI medium. Injections were subcutaneously placed on the right hind limb of each mouse and tumors were allowed to grow until they reached approximately 250 mm³. Nimesulide treatment was administered orally via drinking water and the water was changed daily for 14 days. Initial studies to test for toxicity and demonstrate effects on tumor growth were performed at a nimesulide concentration of 5 μg/g. An additional study was conducted to determine the effects of combining radiation and the inhibitor. In this study, there were two treatment groups (30 Gy and 30 Gy + 5 μg/g nimesulide) and an untreated control group, each having an n=10. Each radiation treatment group received 30 Gy of X-radiation, 3 Gy/fraction for 10 consecutive days. Nimesulide was administered one day prior to the first fraction of radiation. Mice were weighed and tumors were measured weekly. Tumors were measured and irradiated according to previous studies (18). Slopes were calculated using the general trend lines of each treatment group. Once tumors reached ~2000 mm³ mice were sacrificed according to a protocol approved by the University of Kentucky IACUC Committee.

Cell culture. The human lung carcinoma cell line, A549 (ATCC), was grown in RPMI media (Sigma, St. Louis, MO, USA) containing 10% fetal bovine serum (FBS; Sigma), 1% penicillin/streptomycin, and 1% L-glutamine (Gibco). Cells were maintained in a 95% humidified environment at 37°C/5% CO₂ and media was changed every three days. Exponentially growing A549 cells were trypsinized with a 0.05% trypsin solution and 5x10⁴ cells were seeded into 75-cm² filtered flasks. Nimesulide (Sigma) was solubilized in DMSO and administered directly to cells with a DMSO concentration not exceeding 1%. In vitro irradiation was performed in a Phillips Industrial X-Ray Irradiator (Yxlon International Inc., Mogadore, OH, USA).

Colony survival assays. A549 cells were split from stock and seeded into 25-cm² flasks at concentrations of 250-8000 cells per flask depending upon the dose of nimesulide and irradiation (n=4 per treatment group). After 24 h, cells were treated with varying doses of nimesulide that ranged from 0-300 μM and doses of radiation that ranged from 0-4 Gy. For groups treated with both nimesulide and radiation, nimesulide was delivered to cells 2 h prior to radiation. Cells were incubated following all treatments for 24 h and media was then changed. The undisturbed cells were then allowed to incubate for 15 days at which time they were rinsed with saline, stained and fixed with a methanol/crystal violet solution, and then colonies were counted based on the requirement that a colony must contain at least 50 cells. The surviving fraction for each treatment group was normalized to the surviving fraction of the control (plating efficiency).

Western blot analysis. A549 cells were seeded 1x10⁶ in 75-cm² filtered flasks and allowed to grow to ~85% confluence (n=3). To observe the effects of nimesulide combined with radiation, we treated cells 2 h prior to radiation with 100 and 300 μM nimesulide. We then radiated treated and control groups with a dose of 6 Gy and allowed the cells to incubate for 22 additional hours at which time cells were harvested. Protein concentrations were analyzed using a standard Bradford protein assay (Bio-Rad Laboratories, Richmond, CA, USA). 30 μg of protein was separated on a 12% SDS-polyacrylamide electrophoresis mini gel at 120 V for 1 h. Proteins were then transferred to a nitrocellulose membrane (Schleicher & Schuell, Keene, NH, USA) at 100 V for 1.5 h. Membranes were probed with anti-MnSOD (Upstate) at a dilution of 1:3000, survivin
(Novus) at a dilution of 1:2000, and then stripped for 45 min at 55˚C and normalized to anti-ß-actin (Sigma) with a dilution of 1:2000. Measurement and detection of proteins were determined as previously demonstrated (18,19).

**Statistical analysis.** Statistical analysis of *in vitro* studies was performed by one-way ANOVA and Newman-Keuls post test. Nimesulide and radiation interaction was determined by two-way ANOVA and a Bonferroni post test. Tumor sizes were analyzed by using protected LSD to test for differences.

**Results**

**Nimesulide improves radiation efficacy in vivo.** Preliminary investigations demonstrated that nimesulide administered continuously for 14 days initially delayed tumor growth. However, once treatment ended, tumors resumed rapid unabated growth and eventually reached the maximum allowable size, 2000 mm³, at the same time as the untreated group (Fig. 1). Mice treated with the same dose of nimesulide continuously for 50 days demonstrated a significant delay in tumor growth (Fig. 1) without indication of overt toxicity based upon body weights. However, once treatment ended, tumor growth significantly increased and tumors reached their maximum allowable volume one week following the end of treatment. When combined with 30 Gy fractionated radiation, groups that were treated with nimesulide for 14 days exhibited a significant increase in tumor growth delay as compared to radiation alone [p<0.05 (Fig. 2)]. Consistent with these findings, it took nearly 15 days longer for tumors treated with nimesulide and radiation to reach 50% of the allowable tumor size in comparison to the radiation control group and the slope of the growth trend was nearly 46% less than the same group (Table I).

**Clonogenic survival demonstrates improved radiation sensitivity in vitro.** The radiation sensitivity of A549 cells was evaluated in the absence or presence of increasing concentrations of nimesulide. Cells were exposed to graded doses of X-radiation (0-4 Gy) and/or increasing doses of nimesulide (0-300 μM) and allowed to form colonies. Fig. 3 displays the surviving fraction of A549 cells treated with radiation alone,
Table I. Number of days for tumors within a treatment group to reach 1000 mm³ (50% of the allowable tumor size) and slope of each respect growth trend.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Days</th>
<th>Slope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (Untreated)</td>
<td>15.80</td>
<td>201.32</td>
</tr>
<tr>
<td>30 Gy X-radiation</td>
<td>57.80</td>
<td>62.943</td>
</tr>
<tr>
<td>Nimesulide 5 μg/g + 30 Gy</td>
<td>72.20</td>
<td>34.064</td>
</tr>
</tbody>
</table>

Figure 3. Clonegenic survival assay demonstrating radiosensitizing effects of nimesulide in a dose-dependent fashion. Nimesulide significantly sensitized A549 cells to radiation between the dose range of 0 and 4 Gy. Nimesulide was given 2 h prior to radiation treatment and the medium was changed 24 h later. Two-way ANOVA demonstrated a significant interaction between radiation and nimesulide (p<0.0001).

Figure 4. Nimesulide suppresses survivin and radiation-induced MnSOD protein levels following 24 h treatment. A 2-h pretreatment of nimesulide inhibits radiation-induced MnSOD levels confirming inhibition of NF-κB activity.

Discussion

In recent years there has been a great amount of emphasis placed on the investigation of COX-2 inhibitors as potent anticancer agents, specifically in correlation with colon cancer. However, in recent months we have seen the negative implication of certain COX-2 inhibitors as being related to the increase in risk of cardiotoxicity (20-22). While these findings are problematic for long-term use, the possibilities of using COX-2 inhibitors for a short term in combination with ionizing radiation therapy are intriguing. Several studies have shown that COX-2 inhibitors reduce the growth of tumors in vivo and in vitro and can enhance the radiosensitivity of certain tumors (23-29). While there has been a great deal of research and speculation on the exact mechanism by which COX-2 inhibitors produce their anti-tumor effect, there has been no definitive answer to explain the phenomenon or how COX-2 inhibitors enhance the effects of radiation therapy.

NF-κB is an important transcription factor in cytoprotection against several diverse forms of redox-related stresses including radiation. Following radiation treatment, increased activity of NF-κB induces cytoprotective genes such as sod 2 (MnSOD). MnSOD is a primary antioxidant responsible for scavenging superoxide in the mitochondria. It has been shown in previous studies that radiation-induced MnSOD protein leads to enhanced radiation resistance (18,31-33). It has also been shown that PGE₂, a major product of arachidonic metabolism, can activate NF-κB via the transactivation domain of Rel A (15). Upon radiation insult, an influx of arachidonic acid from the membrane is released into the cytosol for metabolism during the cell's inflammation response. This further promotes the concept that NF-κB can be induced during radiation treatment as well as other inducers of oxidative stress including inflammation. In this study, we demonstrate that nimesulide will improve the efficacy of fractionated radiation therapy against non-small cell lung cancer, in part, by suppressing radiation induced NF-κB activation and subsequent MnSOD and survivin protein levels.

In vitro, we demonstrate that nimesulide can improve radiation therapy against NSCLC using a clonogenic survival assay. This effect is most readily observed at lower doses of radiation, between 0-4 Gy of IR. This is a significant finding suggesting that, at doses relevant to clinical fractionated radiation, nimesulide may prove to enhance tumor radiosensitization. In addition to this, we also observed the effects of nimesulide alone and in combination with radiation on the NF-κB target gene products MnSOD and survivin. We found that at 24 h there was a dose-dependent decrease of MnSOD and survivin levels at nimesulide concentrations of 100-300 μM while nimesulide also suppressed the inducible levels of MnSOD following radiation.
In addition to the *in vitro* assays that helped us determine the mechanism of nimesulide action, the effect of the inhibitor in an *in vivo* model via a tumor regrowth assay was tested to access the potential of short-term nimesulide use to improve the radiation effect against tumor growth. Initial studies revealed that administering nimesulide through drinking water had little to no effect on tumor growth when given for a 14-day period without radiation. However, when nimesulide at a concentration of 5 μg/g b.w. was delivered in combination with 50 Gy fractionated radiation, we found a significant reduction in tumor growth in comparison to nimesulide and radiation control groups. It is important to note that when nimesulide was delivered, with or without radiation, there was no reduction in body weight, indicating the absence of overt toxicity.

Previously mentioned studies have shown that COX-2 inhibitors delivered to animals without radiation can slow tumor growth. This was not clearly demonstrated in our model where nimesulide was administered for the shortest time frame. However, groups treated with 5 μg/g nimesulide for 50 days, as compared to those treated for 14 days, demonstrated impaired tumor growth without overt toxicity. This information suggests that while nimesulide, when given alone, may have a more significant effect during prolonged administration, when coupled with radiation, short-term use of nimesulide improves overall radiation sensitivity without overt toxicity.

In summary, our results suggest that there is a pertinent role for COX-2 inhibitors, such as nimesulide, in a dual modality therapy approach with radiation for the treatment of non-small cell lung cancer. We have demonstrated that nimesulide can improve the efficacy of fractionated X-radiation by suppressing the redox sensitive NF-κB leading to the reduction of cytoprotective proteins such as MnSOD and survivin. Future studies should investigate dosing at different time intervals as well as the non-specific interactions of COX-2 inhibitors which may lead to altered tumor growth patterns. Overall, it seems that there is good evidence that nimesulide and related COX-2 inhibitors can improve the efficacy of fractionated X-radiation by a more significant effect during prolonged administration, when coupled with radiation, short-term use of nimesulide improves overall radiation sensitivity without overt toxicity.

Acknowledgements

This study was supported by Kentucky Lung Cancer Research Program and NIH Grant T32 DK07778.

References


